JPRN-UMIN000005086
Completed
Phase 2
Phase II trial of induction gefitinib followed by cisplatin and docetaxel with concurrent radiotherapy in locally advanced non-small cell lung cancer with EGFR activating mutation - Phase II trial of induction gefitinib followed by cisplatin and docetaxel with concurrent radiotherapy in locally advanced non-small cell lung cancer with EGFR activating mutation
ung Oncology Group in Kyushu, Japan (LOGIK)0 sites21 target enrollmentFebruary 15, 2011
Conditionsnon-small cell lung cancer
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- non-small cell lung cancer
- Sponsor
- ung Oncology Group in Kyushu, Japan (LOGIK)
- Enrollment
- 21
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •1\) Patients having EGFR gene mutation (T790M) 2\) Past history of drug hypersensitivity 3\) Patients with superior vena cava (SVC) syndrome 4\) pulmonary fibrosis or interstitial pneumonitis evident on chest CT 5\) serious heart dosease 6\) Psychiatric disorder 7\) uncontrollable diabetes 8\) paresis of intestine, intestinal obstruction 9\) Patients with active severe infections 10\) serious complications other 11\) Patients with active concomitant malignancy 12\) Pregnant or lactation women, or women with known or suspected pregnancy 13\) Inappropriate to entry by physician
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
A phase II trial of gefitinib in combination with bevacizumab as first line therapy for advanced non-small-cell lung cancer with mutated EGFRnon-small-cell lung cancerJPRN-UMIN000004296Okayama Lung Cancer Study Group42
Recruiting
Phase 1
A Phase I/II trial to evaluate gefitinib and concurrent postoperative chemoradiation in patients with advanced resectable head and neck cancerACTRN12605000510640peter maccallum Cancer Centre70
Completed
Phase 2
Phase II trial of gefitinib plus pemetrexed after the relapse to gefitinib in the patients with non-small-cell lung cancer harboring EGFR gene mutations.SCLCJPRN-UMIN000010709Hanshin-Saga Collaborative Cancer Study Group45
Completed
Not Applicable
A phase II study of gefitinib as first-line treatment for elderly patients with advanced lung adenocarcinoma who have active EGFR mutationslung adenocarcinomaJPRN-UMIN000002783agano lung cancer study meeting15
Completed
Phase 2
Phase II study of gefitinib therapy inserted by chemotherapy as first line treatment for advanced non-small cell lung cancer harboring epidermal growth factor receptor (EGFR) mutatioon-small-cell lung cancerJPRN-UMIN000001738Thoracic Medical Oncology, National Cancer Center Hospital33